Medrx Co

Medrx Co Rule of 40

The Rule of 40 of Medrx Co (4586.T) as of Oct 25, 2026 is -785.79 %. In the previous year, Rule of 40 was 462.90 % — a change of -269.75% (lower).

Rule of 40

-785.79 %

YoY

-269.75%

Last updated:

Rule of 40 of Medrx Co is 2025 -785.79 % . Rule of 40 of Medrx Co was 2024 462.90 % . It decreases by -269.75% lower compared to the previous year.

The Medrx Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-15,260.35 JPY
Jan 1, 2019
964.44 JPY
Jan 1, 2020
-1,014.43 JPY
Jan 1, 2021
-12,802.03 JPY
Jan 1, 2022
-1,249.46 JPY
Jan 1, 2023
-3,211.34 JPY
Jan 1, 2024
462.90 JPY
Jan 1, 2025
-785.79 JPY
The Medrx Co Rule of 40 history
YEARRule of 40YoY
-785.79 %-269.75%
462.90 %-114.41%
-3,211.34 %+157.02%
-1,249.46 %-90.24%
-12,802.03 %+1,161.99%
-1,014.43 %-205.18%
964.44 %-106.32%
-15,260.35 %-5,674.25%
273.77 %-104.52%
-6,051.02 %+131.35%
-2,615.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Rule of 40 of Medrx Co is -785.79 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Medrx Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Medrx Co

All Key Metrics — Medrx Co